Spironolactone prevents hyperkaleamia in transgender teens

09 Apr 2019


According to data, published in the Journal of the Endocrine Society, only 2.2% of transgender adolescents treated with spironolactone developed hyperkalemia after starting initiation therapy.

Healio


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story